- Home
- FOLD vs TERN Comparison
FOLD vs TERN Comparison
Compare FOLD & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOLD | TERN |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | 2006 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FOLD | TERN |
|---|---|---|
| Price | $14.49 | $52.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $27.25 | ★ $45.22 |
| AVG Volume (30 Days) | 2.5M | ★ 6.2M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $18.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.66 | $3.55 |
| 52 Week High | $14.50 | $53.19 |
Technical Indicators
Market Signals| Indicator | FOLD | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 74.18 | 74.51 |
| Support Level | $14.21 | $52.42 |
| Resistance Level | N/A | $53.19 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.00 | -0.31 |
| Stochastic Oscillator | 100.00 | 97.30 |
Price Performance
Historical ComparisonAbout FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.